Certain immunocytokines can modulate the activity of leukocytes at the tumor site.
They mediate the influx of T cells and NK cells into the tumor mass.
Various anticancer immunocytokines are being studied in clinical trials.
Intratumoral administration is being considered for neo-adjuvant purposes.